$SHAKESPEAR

Ticker: GOSS Company Name: Gossamer Bio Inc. Trading @ 10.67 CNN Money Analysts Link: https://money.cnn.com/quote/forecast/forecast.html?symb=GOSS Price Target: $12 - $29 Pipeline: Seralutinib (GB002): Inhaled PDGFR, CSF1R, c-KIT inhibitor; Phase 2 ongoing -What is it? GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH) -   Condition:   Pulmonary Arterial Hypertension - Description: The primary objective for this trial is to determine the effect of GB002 on improving pulmonary hemodynamics in subjects with the World Health Organization (WHO) Group 1 PAH who are Functional Class (FC) II and III. The secondary objective for this trials to determine the effect of GB002 on improving exercise capacity in this population. ClinicalTrials.gov: https://clinicaltrials.gov/ct2/show/NCT04456998 Last news:) Pharrmacologic Characterization of GB002, a Novel Inhaled PGGFR Kinase Inhibitor in Development for Pulmonary Arterial Hypertension (PAH ) 2. GB004 - Ulcerative...

  Hello everyone, welcome to another research, I hope everyone is having a great weekend or will have a great weekend. Please be responsible with your money, this is plain research and please advise me on any mistakes. I am not advising anyone about anything, you are responsible for your own money. With that said, let's take-off! ALL: PLEASE READ THE DISCLAIMER AT THE END OF THIS POST Ticker: XFOR Company Name: X4 Pharmaceuticals Inc. Trading @ ~8.39 Friday close. CNN Money Analysts Link: https://money.cnn.com/quote/forecast/forecast.html?symb=XFOR Price Target: $14 - $23 (low to high) From BioPharmCatalyst & Official Site ( https://www.x4pharma.com/pipeline/pipeline/ ) Upcoming Drugs: Mavorixafor and ibrutinib — Waldenström macroglobulinemia Mavorixafor (X4P-001) — Phase 1/2 Severe Congenital Neutropenia (SCN) Mavorixafor (X4P-001) — Phase 3 WHIM syndrome Drug Pipeline: 4. Mavorixafor and axitinib — Phase 2a Renal Cell Carcinoma (RCC) - cancer *** Note: please review the info...

Ticker: ETTX Company Name: Entasis Therapeutics Holdings Inc. Trading @ 3.11 CNN Money Analysts Link: https://money.cnn.com/quote/forecast/forecast.html?symb=ETTX Price Target: $5 - $9 News: Benzinga: https://www.benzinga.com/pressreleases/21/01/g19317814/entasis-therapeutics-announces-sulbactam-durlobactam-expanded-access-program-for-patients-in-the-u From BioPharmCatalyst & Company Website: https://www.biopharmcatalyst.com/company/ETTX https://www.entasistx.com/pipeline SULBACTAM-DURLOBACTAM (ETX2514SUL) - A multidrug resistant Acinetobacter infections — Phase 3 - Durlobactam (DUR; previously designated ETX2514) is our novel, broad-spectrum and potent inhibitor of Class A, C, and D β-lactamases. Sulbactam (SUL) is a β-lactam antibiotic with activity against Acinetobacter baumannii; however, β-lactamase-mediated resistance to sulbactam is now widespread rendering it generally ineffective. In preclinical studies, durlobactam inhibits the β-lactamases commonly found in...